Professor Robert Fern
Professor in Translational Neurobiology
Biomedical Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of Medicine and De
Education 1992 Ph.D., University College London, Universityof London.
1988 HDQC (B.Sc.), St Thomas's, University of London.
Post-Doc,Department of Neurology, Yale University.
2013-present Professor, University of Plymouth
2010-2013 Professor, University ofLeicester.
2002-2010 Reader in Neuroscience,University of Leicester.
2002-2011 Affiliate Faculty Neurology,University of Washington.
1996-2002 AssistantProfessor, Department of Neurology, University of Washington.
1994-1996 Associate Research Scientist,Department of Neurology, Yale University.
2004-2011 Graduate Medical DegreeCommittee, University of Leicester.
2003-2005 Board of Studies, School ofBiological Science, University of Leicester.
2003 Graduate Tutor, CellPhysiology and Pharmacology, University of Leicester.
2002-2012 Seniorplanning group, Cell Physiology and Pharmacology, University of Leicester.
2002 Member of Study SectionMDCN-3, NINDS.
2001-2002 Director, Cell Imaging Core.University of Washington.
1999-2002 Independent Study in MedicalScience coordinator. University of Washington.
1999-2002 Scientific Board, Pediatric EpilepsyResearch Council. University of Washington.
1996-2002 Affiliate, Center on HumanDevelopment and Disability, University of Washington.
My laboratory is primarily interested in the kinds of injury that occurs in the brain following loss of blood supply. These ischemic injuries may take place in he adult brain, leading to stroke; or in the developing nervous system,leading to cerebral palsy. Stroke is the third biggest killer in Western society while cerebral palsy is the most common neurological disorder of infancy, affecting 3:1000 babies. Neither stroke nor cerebral palsy have affective treatments and we are working to understand how the brain cells are injured in these disorders so that we can intervene.
Grants & contracts
2014-2018 “Tackling autophagy and apoptosis for thepotential therapy of Huntington's Disease” PI: Shouqing Luo. £515,000 CI:R. Fern: 5% effort. MRC (MR/M023605/1)
2014-2018 “Toxicant-inducedsynaptic dysfunction and neurotoxicity in Parkinson's disease”. NIH(R01 ES22274-01A1). PI: Kim Tieu. $737,220 CI: R.Fern: 5% effort
2014-2017 “Manipulatingmitochondrial dynamics as a potential therapeutic strategy for Parkinson'sdisease”. PI: Kim Tieu. £511, 230 MRC (MR/L022079/1) CI: R.Fern: 5% effort.
2013-2016 “Ion regulation in CNS whitematter.” Direct costs: £450,000.BBSRC.
2005-2007 "A new paradigm in ischemic brain diseases." Direct costs: £28,480. Medisearch, Leicester.
2004-2006 "Voltage-gated calcium channels in developing central axons." Direct costs: £35,600. Medisearch, Leicester.
2002-2009 "Ischemic injury of neonatal CNS white matter." Direct costs: $1,150,000. National Institutes of Health. USA.
1999 Infrastructure supplement. Direct costs: $50,000.National Institutes of Health. USA.
1997-2002 "Ischemici njury of neonatal CNS white matter." Direct costs: $345,000. National Institutes of Health, USA.
Key publications are highlightedJournals